Federal grants to Mucommune LLC
Mucommune LLC in Durham, North Carolina received $18.4 million in federal grants from fiscal 2021 to 2025, across 21 awards. Its largest program was Allergy and Infectious Diseases Research, with $7.8 million. In fiscal 2025 it was awarded $6.1 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$18.4 million
- Awards21
- Awarded in FY 2025$6.1 million
- Largest award$2.4 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 7 | $4.0 million |
| FY 2022 | 7 | $4.1 million |
| FY 2023 | 4 | $2.9 million |
| FY 2024 | 2 | $1.3 million |
| FY 2025 | 9 | $6.1 million |
Programs that fund Mucommune LLC
| Program | Awards | Amount |
|---|---|---|
| Allergy and Infectious Diseases Research | 9 | $7.8 million |
| Child Health and Human Development Extramural Research | 8 | $7.7 million |
| Cancer Treatment Research | 3 | $2.6 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 1 | $359,608 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 21 | $18.4 million |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Sbir: in vivo validation and ind-enabling development of MM004, a bispecific inhaled immunotherapy for rsv and mpv - project summary respiratory syncytial virus (RSV) and metapneumovirus (MPV) are the two leading viral causes of death in infants and young children, and are major causes of respirator | Allergy and Infectious Diseases Research | March 4, 2021 | $2.4 million |
| Ind?enabling development of mm?008 ivr, an antibody-based nonhormonal contraceptive intravaginal ring - summary nearly half of all pregnancies in the U.S. Are unintended, and most occur in women who are not using contraceptives. There are diverse reasons for not using contraceptives; one common reas | Child Health and Human Development Extramural Research | September 19, 2022 | $2.1 million |
| Nonhormonal contraceptive intravaginal ring based on high valency anti-sperm antibody constructs - summary nearly half of all pregnancies in the U.S. Are unintended, and most occur in women who are not using contraceptives. There are diverse reasons for not using contraceptives; one common reason is | Child Health and Human Development Extramural Research | August 24, 2021 | $1.7 million |
| Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIV | Child Health and Human Development Extramural Research | January 25, 2021 | $1.7 million |
| Development of respiraclear for targeted mucosal treatment of rsv infections | Allergy and Infectious Diseases Research | May 7, 2021 | $1.5 million |
| Sbir: in vivo engineering of multifaceted B7H3.car-t cells for cellular immunotherapy of pancreatic ductal adenocarcinoma - project summary t-cells modified with chimeric antigen receptor against unique cancer antigens i.e., car-t, represent a promising form of immunotherapy for cancer, but are curr | Cancer Treatment Research | September 15, 2025 | $1.1 million |
| Fast dissolving MM008 tablet for instant on-demand non-hormonal contraception - project summary nearly half of all pregnancies in the U.S. Are unintended, and most occur in women who are not using contraceptives. There are diverse reasons for not using contraceptives; one common reason is that many | Child Health and Human Development Extramural Research | September 12, 2025 | $1.1 million |
| Sbir: in vivo engineering of B7-H3.car-t cells for ovarian cancer therapy - project summary t-cells modified with chimeric antigen receptor against unique cancer antigens i.e., car-t, represent a promising form of immunotherapy for cancer, but are currently limited by production time and costs to pr | Cancer Treatment Research | September 10, 2025 | $1.0 million |
| Ind-enabling development of MM-009, a reservoir-intravaginal ring for ultra-highrates of month-long lactic acid release to treat and prevent bacterial vaginosis - summary millions of women in the U.S. Suffer from bacterial vaginosis (BV), a vaginal condition characterized by marked overgrowth of pol | Allergy and Infectious Diseases Research | June 23, 2025 | $1.0 million |
| In vivo dose finding for IN-002 in neonatal lambs for inhaled immunotherapy of rsv | Allergy and Infectious Diseases Research | November 27, 2020 | $995,652 |
Questions people ask
How much federal grant money does Mucommune LLC get?
$18.4 million in 21 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Mucommune LLC the most?
The Department of Health and Human Services, with $18.4 million in 21 awards.
What is Mucommune LLC's largest federal grant?
$2.4 million under Allergy and Infectious Diseases Research, with its first action in the period on March 4, 2021. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Mucommune LLC?
Its largest are Allergy and Infectious Diseases Research, Child Health and Human Development Extramural Research and Cancer Treatment Research.
Other grant recipients in Durham
- Duke University
- Family Health International
- North Carolina Central University
- Housing Authority of the City of Durham
- Rho Federal Systems Division Inc
- City of Durham
- Families & Communities Rising, Inc.
- Lincoln Community Health Center Incorporated
Largest federal grant recipients in North Carolina · Federal grants in North Carolina